PartitionBio and Gene Weaver Announce Exclusive Partnership to Advance Programmable Gene Insertion Delivery
Cambridge, UK – Tuesday 16 September 2025
PartitionBio, a biotechnology company pioneering advanced biologics delivery technologies, today announced a strategic collaboration with Gene Weaver, an innovation-driven company specialising in programmable gene insertion. The agreement grants Gene Weaver an exclusive worldwide license to utilise PartitionBio’s BubbleFect biologics delivery platform to deliver its proprietary gene insertion technology into mammalian cells.
This collaboration leverages the complementary strengths of both companies. BubbleFect technology enables efficient intracellular delivery of biological cargos, including proteins, RNA, DNA, and multi-component complexes, while Gene Weaver’s programmable gene insertion technology represents a disruptive approach to precise genome modification. By combining these platforms, the partnership aims to develop optimised methods for targeted gene delivery in vitro and in vivo, potentially surpassing the efficiency and versatility of current lipid-based delivery methods.
PartitionBio’s mission is to establish BubbleFect as a leading method for delivering biological materials into mammalian cells. This partnership represents an opportunity to integrate BubbleFect with novel cell modification technologies from an early stage, demonstrating the platform’s broad applicability for diverse biological cargos. It also complements PartitionBio’s strategic objective to expand market penetration through targeted partnering and licensing agreements in the rapidly growing field of intracellular biologics delivery.
Gene Weaver’s pioneering gene editing and manipulation technologies align closely with PartitionBio’s emphasis on innovation. Advanced gene editing approaches are prime candidates for delivery optimisation via PartitionBio reagents, creating multiple potential applications across research and therapeutic settings.
BubbleFect provides the ability to deliver large, multi-component payloads effectively into cells. Gene Weaver’s technology, which requires coordinated delivery of multiple components, stands to benefit from BubbleFect’s flexibility in delivering complexes in fully assembled forms or as RNA/DNA precursors. The combination of BubbleFect and Gene Weaver’s platform may enhance delivery efficiency and precision, offering researchers a robust alternative to existing lipid-based methods. Additionally, the collaboration could facilitate commercial adoption without the constraints of complex intellectual property landscapes common in gene editing and lipid nanoparticle technologies.
“This partnership reflects our shared view that highly synergistic technologies should be combined early in development to maximise the likelihood of success,” said Niall Armes, Founder of PartitionBio.
“Both BubbleFect and Gene Weaver’s platform technologies have broad independent potential, but together they may unlock new efficiencies and applications for intracellular delivery of complex biologics.”
The companies anticipate that this collaboration will catalyse new research and therapeutic opportunities by integrating leading-edge delivery methods with cutting-edge gene insertion technologies.